Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
IMpact-RSV Study Group - Pediatrics, 1998 - publications.aap.org
Objective. To determine the safety and efficacy of prophylaxis with palivizumab in reducing
the incidence of hospitalization because of respiratory syncytial virus (RSV) infection in high-
risk infants. Methods. A randomized, double-blind, placebo-controlled trial was conducted at
139 centers in the United States, the United Kingdom, and Canada. During the 1996 to 1997
RSV season, 1502 children with prematurity (≤ 35 weeks) or bronchopulmonary dysplasia
(BPD) were randomized to receive 5 injections of either palivizumab (15 mg/kg) or an …
the incidence of hospitalization because of respiratory syncytial virus (RSV) infection in high-
risk infants. Methods. A randomized, double-blind, placebo-controlled trial was conducted at
139 centers in the United States, the United Kingdom, and Canada. During the 1996 to 1997
RSV season, 1502 children with prematurity (≤ 35 weeks) or bronchopulmonary dysplasia
(BPD) were randomized to receive 5 injections of either palivizumab (15 mg/kg) or an …